NASDAQ NMS - GLOBAL MARKET · FATE
+2.79% · +$0.0650 · Vol 1.0M
Live · updated 15:35:29 ET
Fate Therapeutics Inc

Fate Therapeutics Inc

Biotechnology
$2.40
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
Analyst data unavailable at compute time
FATE
Fate Therapeutics Inc
Fri Aug 21 · last completed session · daily score · 2d 21h old
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

32/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Fri Aug 21 · last completed session · daily score · 2d 21h old
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is FATE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading FATE catalysts
About Fate Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2013
Employees
161
Country
US

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.34
Day high
$2.42
Day low
$2.23
Previous close
$2.33
52W high
$3.11
-22.99% from high
52W low
$0.9500
67% of range
Market cap
$279.2M
EPS
$-1.0700
Beta
2.09
Shares out
119.8M
Volume
1M
0.47× rel vol
Avg volume
2.2M
VWAP
$2.34
Price history computed in-house
1W
-8.59%
1M
-0.62%
3M
+11.40%
1Y
+108.26%
YTD
+143.74%
SMA 50 $2.54 · below
SMA 200 $1.65 · above
52W position 67%

FATE overview

Veridion Score
32
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
1
Daniel Goldman · Sale
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around FATE.Congress disclosuresOpen receipt and filing context for FATE.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading FATE Form 4 filings
Public disclosures

Congress activity in FATE

Congress trackerOpen ticker disclosure ledger →
Federal contracts

FATE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for FATE in this window.
Lobbying spend

FATE lobbying filings, year to date.

Registered lobbying filings matched to Fate Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for FATE in this window.
Loading news for FATE
Analyst ratings
Sovereign unlock shows live analyst consensus for FATE.
Options
Sovereign unlock shows live options positioning for FATE.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.